Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)

Tom Stinchcombe, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto E. Villegas, Dariusz Kowalski, Christina S. Baik, Dolores Isla, Javier De Castro, Pilar Garrido Lopez, Achim Rittmeyer, Marcello Tiseo, Sven Franz Stanzel, Sanne de Haas, Lisa Lam, Michael Lu, Solange Peters

Duke University, Durham, NC
University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland
University Hospital Basel, Institute of Pathology, Basel, Switzerland
Rush University Medical Center, Chicago, IL
Cancer Specialists of North Florida, Jacksonville, FL
Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland
University of Washington, Seattle, WA
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Ramón y Cajal, Madrid, Spain
Fachklinik für Lungenerkrankungen, Immenhausen, Germany
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Genentech, Inc., San Francisco, CA
Lausanne University Hospital, Lausanne, Switzerland